한글목차

세계의 RWE(Real-World Evidence) 솔루션 시장은 2024년에 29억 8,000만 달러로 평가되었으며, 2030년까지 CAGR 8.99%로 성장하여 50억 달러에 달할 것으로 예측됩니다.

세계 RWE(Real-World Evidence) 솔루션 시장은 실제 데이터로부터 임상적 지식을 수집, 분석, 생성하고 다양한 의료 의사결정에 정보를 제공하기 위해 활용되는 종합적인 기술과 서비스를 포함합니다. 이 시장은 주로 의약품 개발 및 승인에서 RWE에 대한 규제적 수용성 확대, 가치 기반 의료 모델에 대한 수요 증가, 효율적인 시판 후 조사의 필요성 증가에 의해 주도되고 있습니다.

주요 시장 촉진요인

세계 RWE(Real-World Evidence) 솔루션 시장은 규제 당국의 수용성 확대와 가치 기반 의료 모델로의 전환에 따라 근본적으로 영향을 받고 있습니다. 전 세계 규제 당국은 의약품 개발 및 시판 후 조사에 리얼월드 증거를 점차적으로 도입하고 있습니다.

주요 시장 과제

단편화된 세계 의료 시스템 전반의 데이터 상호운용성 및 표준화에 대한 지속적인 도전은 세계 RWE(Real-World Evidence) 솔루션 시장의 성장을 직접적으로 저해하고 있습니다. 이 문제는 전 세계 다양한 임상 현장, 전자건강기록 시스템, 행정 데이터베이스에서 생성되는 실세계 데이터에 널리 나타나는 다양한 형식, 용어 체계, 거버넌스 구조에서 기인합니다.

주요 시장 동향

인공지능(AI)과 머신러닝(ML)을 실제 증거(RWE) 분석에 통합하는 것은 복잡한 데이터세트에서 깊은 인사이트를 얻을 수 있는 능력을 강화하는 혁신적인 추세입니다. 이러한 첨단 기술은 보다 효율적인 데이터 처리, 패턴 식별, 예측 모델링을 가능하게 하여 의약품 개발 가속화 및 치료 경로 최적화에 필수적입니다.

목차

제1장 개요

제2장 조사 방법

제3장 주요 요약

제4장 고객의 소리

제5장 세계의 RWE(Real-World Evidence) 솔루션 시장 전망

• 시장 규모 및 예측
  • 금액별
• 시장 점유율과 예측
  • 구성요소별(청구 데이터, 임상 현장 데이터, 환자 주도 데이터, 약국 데이터, 기타 구성요소)
  • 치료 분야별(종양학, 면역학, 신경학, 심혈관질환, 기타 치료 분야)
  • 지역별
  • 기업별(2024)
• 시장 맵

제6장 북미의 RWE(Real-World Evidence) 솔루션 시장 전망

• 시장 규모 및 예측
• 시장 점유율과 예측
• 북미 : 국가별 분석
  • 미국
  • 캐나다
  • 멕시코

제7장 유럽의 RWE(Real-World Evidence) 솔루션 시장 전망

• 시장 규모 및 예측
• 시장 점유율과 예측
• 유럽 : 국가별 분석
  • 독일
  • 프랑스
  • 영국
  • 이탈리아
  • 스페인

제8장 아시아태평양의 RWE(Real-World Evidence) 솔루션 시장 전망

• 시장 규모 및 예측
• 시장 점유율과 예측
• 아시아태평양 : 국가별 분석
  • 중국
  • 인도
  • 일본
  • 한국
  • 호주

제9장 중동 및 아프리카의 RWE(Real-World Evidence) 솔루션 시장 전망

• 시장 규모 및 예측
• 시장 점유율과 예측
• 중동 및 아프리카 : 국가별 분석
  • 사우디아라비아
  • 아랍에미리트
  • 남아프리카공화국

제10장 남미의 RWE(Real-World Evidence) 솔루션 시장 전망

• 시장 규모 및 예측
• 시장 점유율과 예측
• 남미 : 국가별 분석
  • 브라질
  • 콜롬비아
  • 아르헨티나

제11장 시장 역학

• 성장 촉진요인
• 과제

제12장 시장 동향과 발전

• 인수합병
• 제품 출시
• 최근 동향

제13장 세계의 RWE(Real-World Evidence) 솔루션 시장 : SWOT 분석

제14장 Porter's Five Forces 분석

• 업계내 경쟁
• 신규 참여의 가능성
• 공급업체의 능력
• 고객의 능력
• 대체품의 위협

제15장 경쟁 구도

• Clinigen Group PLC
• Icon PLC
• IBM Corporation
• IQVIA Inc.
• Oracle Corporation
• Parexel International
• PerkinElmer Inc.
• Pharmaceutical Product Development(PPD Inc.)
• SAS Institute Inc.
• Syneos Health Inc.

제16장 전략적 제안

제17장 조사 회사 소개 및 면책사항

영문목차

The Global Real-World Evidence Solutions Market , valued at USD 2.98 Billion in 2024, is projected to experience a CAGR of 8.99% to reach USD 5.00 Billion by 2030. The Global Real-World Evidence (RWE) Solutions Market encompasses the comprehensive technology and services employed for collecting, analyzing, and generating clinical insights from real-world data to inform diverse healthcare decisions. This market is primarily driven by the increasing regulatory acceptance of RWE in drug development and approvals, the growing demand for value-based care models, and the expanding need for efficient post-market surveillance.

Key Market Drivers

The global Real-World Evidence Solutions Market is fundamentally influenced by increasing regulatory acceptance and the profound shift towards value-based healthcare models. Regulatory bodies globally are progressively integrating real-world evidence into drug development and post-market surveillance. This evolution supports accelerated therapy development by validating outcomes derived from routine clinical practice. According to GlobeNewswire, in August 2024, 82% of drug submissions to the FDA included Real-World Evidence, up from 73% in 2022, demonstrating growing reliance on these solutions for regulatory decision-making. This emphasis by regulators highlights the need for robust real-world data collection and analysis.

Key Market Challenges

The persistent issue of data interoperability and standardization across fragmented global healthcare systems directly impedes the growth of the Global Real-World Evidence Solutions Market. This challenge stems from the diverse formats, terminologies, and governance structures prevalent in real-world data generated across various clinical settings, electronic health record systems, and administrative databases worldwide. Consequently, the seamless aggregation and comprehensive analysis of this disparate data are significantly hindered, demanding extensive manual efforts and complex data harmonization processes. This operational complexity escalates the time and resources required to synthesize meaningful clinical insights, thereby diminishing the efficiency and scalability of real-world evidence initiatives.

Key Market Trends

The integration of artificial intelligence (AI) and machine learning (ML) in Real-World Evidence (RWE) analytics represents a transformative trend, enhancing the ability to derive deep insights from complex datasets. These advanced technologies facilitate more efficient data processing, pattern identification, and predictive modeling, which are crucial for accelerating drug development and optimizing treatment pathways. According to eClinical Solutions' 2024 Industry Outlook, 53% of respondents from clinical operations, data management, and biometrics functions believed AI and ML would have the greatest impact on efficiency and outcomes in 2024, signifying growing industry confidence in these tools. For example, IQVIA announced a collaboration with NVIDIA in January 2025, deploying over 50 AI agents trained on 1.2 billion health records to streamline workflows in life sciences, which demonstrates how AI is directly contributing to faster drug discovery timelines and improved decision-making within the RWE solutions market.

Key Market Players

• Clinigen Group PLC
• Icon PLC
• IBM Corporation
• IQVIA Inc.
• Oracle Corporation
• Parexel International
• PerkinElmer Inc.
• Pharmaceutical Product Development (PPD Inc.)
• SAS Institute Inc.
• Syneos Health Inc.

Report Scope:

In this report, the Global Real-World Evidence Solutions Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Real-World Evidence Solutions Market , By Component:

• Claims Data
• Clinical Settings Data
• Patient-Powered Data
• Pharmacy Data
• Other Components

Real-World Evidence Solutions Market , By Therapeutic Area:

• Oncology
• Immunology
• Neurology
• Cardiovascular Disease
• Other Therapeutic Areas

Real-World Evidence Solutions Market , By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Real-World Evidence Solutions Market .

Available Customizations:

Global Real-World Evidence Solutions Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Real-World Evidence Solutions Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Component (Claims Data, Clinical Settings Data, Patient-Powered Data, Pharmacy Data, Other Components)
  • 5.2.2. By Therapeutic Area (Oncology, Immunology, Neurology, Cardiovascular Disease, Other Therapeutic Areas)
  • 5.2.3. By Region
  • 5.2.4. By Company (2024)
• 5.3. Market Map

6. North America Real-World Evidence Solutions Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Component
  • 6.2.2. By Therapeutic Area
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Real-World Evidence Solutions Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Component
      • 6.3.1.2.2. By Therapeutic Area
  • 6.3.2. Canada Real-World Evidence Solutions Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Component
      • 6.3.2.2.2. By Therapeutic Area
  • 6.3.3. Mexico Real-World Evidence Solutions Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Component
      • 6.3.3.2.2. By Therapeutic Area

7. Europe Real-World Evidence Solutions Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Component
  • 7.2.2. By Therapeutic Area
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Real-World Evidence Solutions Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Component
      • 7.3.1.2.2. By Therapeutic Area
  • 7.3.2. France Real-World Evidence Solutions Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Component
      • 7.3.2.2.2. By Therapeutic Area
  • 7.3.3. United Kingdom Real-World Evidence Solutions Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Component
      • 7.3.3.2.2. By Therapeutic Area
  • 7.3.4. Italy Real-World Evidence Solutions Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Component
      • 7.3.4.2.2. By Therapeutic Area
  • 7.3.5. Spain Real-World Evidence Solutions Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Component
      • 7.3.5.2.2. By Therapeutic Area

8. Asia Pacific Real-World Evidence Solutions Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Component
  • 8.2.2. By Therapeutic Area
  • 8.2.3. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Real-World Evidence Solutions Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Component
      • 8.3.1.2.2. By Therapeutic Area
  • 8.3.2. India Real-World Evidence Solutions Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Component
      • 8.3.2.2.2. By Therapeutic Area
  • 8.3.3. Japan Real-World Evidence Solutions Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Component
      • 8.3.3.2.2. By Therapeutic Area
  • 8.3.4. South Korea Real-World Evidence Solutions Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Component
      • 8.3.4.2.2. By Therapeutic Area
  • 8.3.5. Australia Real-World Evidence Solutions Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Component
      • 8.3.5.2.2. By Therapeutic Area

9. Middle East & Africa Real-World Evidence Solutions Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Component
  • 9.2.2. By Therapeutic Area
  • 9.2.3. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Real-World Evidence Solutions Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Component
      • 9.3.1.2.2. By Therapeutic Area
  • 9.3.2. UAE Real-World Evidence Solutions Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Component
      • 9.3.2.2.2. By Therapeutic Area
  • 9.3.3. South Africa Real-World Evidence Solutions Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Component
      • 9.3.3.2.2. By Therapeutic Area

10. South America Real-World Evidence Solutions Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Component
  • 10.2.2. By Therapeutic Area
  • 10.2.3. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Real-World Evidence Solutions Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Component
      • 10.3.1.2.2. By Therapeutic Area
  • 10.3.2. Colombia Real-World Evidence Solutions Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Component
      • 10.3.2.2.2. By Therapeutic Area
  • 10.3.3. Argentina Real-World Evidence Solutions Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Component
      • 10.3.3.2.2. By Therapeutic Area

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Real-World Evidence Solutions Market : SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Clinigen Group PLC
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Icon PLC
• 15.3. IBM Corporation
• 15.4. IQVIA Inc.
• 15.5. Oracle Corporation
• 15.6. Parexel International
• 15.7. PerkinElmer Inc.
• 15.8. Pharmaceutical Product Development (PPD Inc.)
• 15.9. SAS Institute Inc.
• 15.10. Syneos Health Inc.

16. Strategic Recommendations

17. About Us & Disclaimer